Hikma Pharmaceuticals (GB:HIK) has released an update.
Hikma Pharmaceuticals has announced the strategic acquisition of Xellia Pharmaceuticals’ US finished dosage form business, expanding its injectables portfolio and manufacturing capabilities with a $135 million initial payment and up to $50 million in milestones. The deal includes a commercial portfolio, a Cleveland manufacturing plant, and an R&D center in Croatia, expected to enhance Hikma’s growth and injectable medicine production. The acquisition is projected to be earnings-neutral initially but accretive over the longer term, with an immediate revenue contribution of approximately $75 million annually from Xellia’s current products.
For further insights into GB:HIK stock, check out TipRanks’ Stock Analysis page.
